Effect of TTP488 in patients with mild to moderate Alzheimer’s disease

BACKGROUND: TTP488, an antagonist at the Receptor for Advanced Glycation End products, was evaluated as a potential treatment for patients with mild-to-moderate Alzheimer’s disease (AD). A previous report describes decreased decline in ADAS-cog (delta = 3.1, p = 0.008 at 18 months, ANCOVA with multi...

Descripción completa

Detalles Bibliográficos
Autores principales: Burstein, Aaron H, Grimes, Imogene, Galasko, Douglas R, Aisen, Paul S, Sabbagh, Marwan, Mjalli, Adnan MM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021072/
https://www.ncbi.nlm.nih.gov/pubmed/24423155
http://dx.doi.org/10.1186/1471-2377-14-12

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021072/
https://www.ncbi.nlm.nih.gov/pubmed/24423155
http://dx.doi.org/10.1186/1471-2377-14-12

Ejemplares similares